Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834463 | 0.76 | TRPA1 (0.45) | ERCC5FEN1TRPA1TRPV3TRPV4 | |
| SCHEMBL13174943 | 0.75 | TRPA1 (0.44) | ERCC5FEN1TRPA1TRPV3TRPV4 | |
| SCHEMBL16361496 | 0.72 | TRPA1 (0.49) | ERCC5FEN1TRPA1TRPV3TRPV4 | |
| SCHEMBL15474256 | 0.72 | ERCC5 (0.72) | ERCC5FEN1ADORA2B | |
| SCHEMBL16663490 | 0.71 | ERCC5 (0.43) | ERCC5FEN1TRPA1TRPV3TRPV4 | |
| SCHEMBL1803011 | 0.70 | TRPA1 (0.41) | TRPA1TRPV4 | |
| SCHEMBL13835019 | 0.70 | TRPA1 (0.37) | TRPA1ADORA2BUSP2AOC3 | |
| SCHEMBL13075846 | 0.69 | ADORA2B (0.43) | ADORA2BUSP2POLBADORA1L3MBTL1 | |
| SCHEMBL15241235 | 0.68 | ERCC5 (0.40) | ERCC5FEN1TRPA1TRPV3TRPV4 | |
| SCHEMBL13834828 | 0.66 | KDM4E (0.33) | TRPA1TRPV4ADORA2BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| EP-2634191-B1 | Process for preparing derivatives of thienopyrimidinedione | GLENMARK PHARMACEUTICALS SA (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-2634191-A1 | Process for preparing derivatives of thienopyrimidinedione | Glenmark Pharmaceuticals S.A. (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-8507503-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-13 | — | — | US | disclosed |
| EP-2411396-B1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| EP-2411396-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ERCC5 1253/4885FEN1 3078/4885TRPA1 1/4885 |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ERCC5 1253/4885FEN1 3078/4885TRPA1 1/4885 |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | ERCC5 1253/4885FEN1 3078/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.